These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62. Immunohistochemical validation of COL3A1, GPR158 and PITHD1 as prognostic biomarkers in early-stage ovarian carcinomas. Engqvist H; Parris TZ; Kovács A; Nemes S; Werner Rönnerman E; De Lara S; Biermann J; Sundfeldt K; Karlsson P; Helou K BMC Cancer; 2019 Sep; 19(1):928. PubMed ID: 31533654 [TBL] [Abstract][Full Text] [Related]
63. Genomic alterations in gynecological malignancies: histotype-associated driver mutations, molecular subtyping schemes, and tumorigenic mechanisms. Mori S; Gotoh O; Kiyotani K; Low SK J Hum Genet; 2021 Sep; 66(9):853-868. PubMed ID: 34092788 [TBL] [Abstract][Full Text] [Related]
64. Molecular insights into the classification of high-grade endometrial carcinoma. Hussein YR; Soslow RA Pathology; 2018 Feb; 50(2):151-161. PubMed ID: 29246451 [TBL] [Abstract][Full Text] [Related]
65. Transcriptomic and genomic profiling of early-stage ovarian carcinomas associated with histotype and overall survival. Engqvist H; Parris TZ; Rönnerman EW; Söderberg EMV; Biermann J; Mateoiu C; Sundfeldt K; Kovács A; Karlsson P; Helou K Oncotarget; 2018 Oct; 9(80):35162-35180. PubMed ID: 30416686 [TBL] [Abstract][Full Text] [Related]
66. Trefoil factor family proteins as potential diagnostic markers for mucinous invasive ovarian carcinoma. Werner Rönnerman E; Pettersson D; Nemes S; Dahm-Kähler P; Kovács A; Karlsson P; Parris TZ; Helou K Front Oncol; 2022; 12():1112152. PubMed ID: 36818673 [TBL] [Abstract][Full Text] [Related]
67. Validation of Novel Prognostic Biomarkers for Early-Stage Clear-Cell, Endometrioid and Mucinous Ovarian Carcinomas Using Immunohistochemistry. Engqvist H; Parris TZ; Kovács A; Rönnerman EW; Sundfeldt K; Karlsson P; Helou K Front Oncol; 2020; 10():162. PubMed ID: 32133296 [TBL] [Abstract][Full Text] [Related]
68. Morphologic Reproducibility, Genotyping, and Immunohistochemical Profiling Do Not Support a Category of Seromucinous Carcinoma of the Ovary. Rambau PF; McIntyre JB; Taylor J; Lee S; Ogilvie T; Sienko A; Morris D; Duggan MA; McCluggage WG; Köbel M Am J Surg Pathol; 2017 May; 41(5):685-695. PubMed ID: 28125452 [TBL] [Abstract][Full Text] [Related]
69. Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma. Madore J; Ren F; Filali-Mouhim A; Sanchez L; Köbel M; Tonin PN; Huntsman D; Provencher DM; Mes-Masson AM J Pathol; 2010 Feb; 220(3):392-400. PubMed ID: 19967725 [TBL] [Abstract][Full Text] [Related]
70. Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials. Meagher NS; Schuster K; Voss A; Budden T; Pang CNI; deFazio A; Ramus SJ; Friedlander ML Gynecol Oncol; 2018 Sep; 150(3):527-533. PubMed ID: 30054102 [TBL] [Abstract][Full Text] [Related]
71. Genome-wide multi-omics profiling of the 8p11-p12 amplicon in breast carcinoma. Parris TZ; Rönnerman EW; Engqvist H; Biermann J; Truvé K; Nemes S; Forssell-Aronsson E; Solinas G; Kovács A; Karlsson P; Helou K Oncotarget; 2018 May; 9(35):24140-24154. PubMed ID: 29844878 [TBL] [Abstract][Full Text] [Related]